Brief: Kintara Therapeutics Announces Initiation Of Rem-001 Clinical Trial
12/02/2024 14:51
Feb 12 (Reuters) - Kintara Therapeutics Inc KTRA.O :
* KINTARA THERAPEUTICS ANNOUNCES INITIATION OF REM-001
CLINICAL
TRIAL FOR THE TREATMENT OF CUTANEOUS METASTATIC BREAST CANCER
* 15-PATIENT OPEN LABEL STUDY TO CONFIRM PLANNED DOSE AND
OPTIMIZED STUDY DESIGN LEADING TO A PHASE 3 CLINICAL TRIAL IN
CMBC PATIENTS
Source text for Eikon: ID:nPn41JdzDa
Further company coverage: KTRA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TuHURA Biosciences
See all newsBrief: Tuhura Biosciences Receives Key U.S. Patent For Its Groundbreaking Delta Opioid Receptor Antibody Drug Conjugate Technology
TuHURA Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tuhura Biosciences Reports Second Quarter 2026 Financial Results And Provides A Corporate Update
TuHURA Biosciences Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Tuhura Biosciences Inc Enters At The Market Offering Agreement With H.C. Wainwright & Co.